Rue SAntos-DUmont
1
6041 GOSSELIES
Belgium
[email protected] bioxodes.com

Bioxodes is a clinical stage company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in haemorrhagic stroke patients.

About

Related news

News

Learn more
bioxodes2

Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing

    Press release

12.02.2025

Learn more
md-photo-light (1)

Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial

    Press release

19.12.2024